Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Lexicon Pharmaceuticals, Inc./ EFFECT

SEC Filing · EFFECT

Lexicon Pharmaceuticals, Inc.

LXRXNASDAQEQUITYCurrent

SEC Filing

Filed Aug 14, 2026Accepted Aug 17, 2026, 12:15 AM EDTCIK 1062822Accession 9999999995-26-002666
View company →Permanent SEC source ↗
Share

Company context

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications.

Current securities

LXRXNASDAQ · EQUITY · Current

Recent company filings

  1. S-3 filingAug 6, 2026
  2. S-8 filingAug 6, 2026
  3. 10-Q filingAug 6, 2026
  4. Results of Operations and Financial ConditionAug 6, 2026
  5. 4 filingJun 4, 2026

As-filed source

Primary evidence
As filedOpen full document ↗